ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2014
Nivolumab: promising survival signal coupled with limited toxicity raises expectations.
Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed.
- Engineering an immuno-nanoprodrug: Photo-controlled pyroptosis synergizing with acid-activatable immunometabolic blockade for potent cancer immunotherapy.Acta pharmaceutica Sinica. B · 2026Article
- TIGIT in cancer: from mechanism of action to promising immunotherapeutic strategies.Cell death & disease · 2025Review
- Immunotherapy resistance in non-small cell lung cancer: from mechanisms to therapeutic opportunities.Journal of experimental & clinical cancer research : CR · 2025Review
- Targeting novel regulated cell death: Ferroptosis, pyroptosis and necroptosis in anti-PD-1/PD-L1 cancer immunotherapy.Cell proliferation · 2024Review
- Posttranslational regulatory mechanism of PD-L1 in cancers and associated opportunities for novel small-molecule therapeutics.Acta biochimica et biophysica Sinica · 2024Review
- Mechanisms of immune checkpoint inhibitors: insights into the regulation of circular RNAS involved in cancer hallmarks.Cell death & disease · 2024Review
- Unveiling the therapeutic potential: KBU2046 halts triple-negative breast cancer cell migration by constricting TGF-β1 activationOncology research · 2024Article
- Unlocking Benzosampangine's Potential: A Computational Approach to Investigating, Its Role as a PD-L1 Inhibitor in Tumor Immune Evasion via Molecular Docking, Dynamic Simulation, and ADMET Profiling.Bioinformatics and biology insights · 2024Article
- Synthesis and Biological Evaluation of Potential Oncoimmunomodulator Agents.International journal of molecular sciences · 2023Article
- Engineered nanomedicines block the PD-1/PD-L1 axis for potentiated cancer immunotherapy.Acta pharmacologica Sinica · 2022Review
- Serum exosomal miR-16-5p functions as a tumor inhibitor and a new biomarker for PD-L1 inhibitor-dependent immunotherapy in lung adenocarcinoma by regulating PD-L1 expression.Cancer medicine · 2022Article
- The role of lncRNAs and circRNAs in the PD-1/PD-L1 pathway in cancer immunotherapy.Molecular cancer · 2021Review
- Small molecule inhibitors targeting the PD-1/PD-L1 signaling pathway.Acta pharmacologica Sinica · 2021Review
- Putting the Pieces Together: Completing the Mechanism of Action Jigsaw for Sipuleucel-T.Journal of the National Cancer Institute · 2020Review
- Incidence and Management of Immune-Related Adverse Events in Patients Undergoing Treatment with Immune Checkpoint Inhibitors.Current oncology reports · 2018Review
- Urgent Need to Define Pretreatment Predictors of Immune Check Point Inhibitors Related Endocrinopathies: A Case Report and Review of Literature.Journal of translational internal medicine · 2017Article
- Immunotherapy of Prostate Cancer: Facts and Hopes.Clinical cancer research : an official journal of the American Association for Cancer Research · 2017Review
- Recent advances in the management of non-small cell lung cancer.F1000Research · 2017Review
- Harnessing the immune system to improve cancer therapy.Annals of translational medicine · 2016Review
- Considerations for the combination of anticancer vaccines and immune checkpoint inhibitors.Expert opinion on biological therapy · 2016Review
Corrections and comments
- Comment on
Authors and funding
3 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.